Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/31094| Title: | Bone Health and Denosumab Discontinuation in Oncology Populations. | Austin Authors: | Cheung, Yee-Ming Melody ;Morgans, Alicia;Hamnvik, Ole-Petter Riksfjord | Affiliation: | Medicine (University of Melbourne) Department of Medical Oncology, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, MA, USA.. Division of Endocrinology, Diabetes, and Hypertension, Department of Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA.. |
Issue Date: | 17-Oct-2022 | Date: | 2022 | Publication information: | The Oncologist 2022-10-17 | URI: | https://ahro.austin.org.au/austinjspui/handle/1/31094 | DOI: | 10.1093/oncolo/oyac213 | ORCID: | 0000-0003-3875-5698 | Journal: | The Oncologist | PubMed URL: | 36250799 | Type: | Journal Article | Subjects: | bone health cancer denosumab discontinuation multiple vertebral fractures rebound phenomenon |
| Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.